Gelonghui August 29?Shanghai Vanguard Holdings (01345.HK) reported interim results that earnings rose 11.8 per cent to 736.9 million yuan in the six months ended June 30, 2023. The proceeds of drugs sold by providing comprehensive marketing, promotion and channel management services are determined bySix months ended June 30, 2022The decrease of RMB 429.1 million by 52.3% as for the RMB 204.9 million during the reporting period was mainly due to the reduction in the sales prices of some products during the reporting period and the slow recovery of market sales of individual products after the COVID-19 epidemic. The income of medical devices sold by providing comprehensive marketing, promotion and channel management services bySix months ended June 30, 2022The increase of RMB966 million by 311.7% during the reporting period was mainly due to the increase in sales during the reporting period after the Group acquired the agency rights for certain medical device products in Shanghai and Zhejiang in 2022. Revenue from products sold through the provision of channel management services is determined bySix months ended June 30, 2022The amount of RMB 133.7 million increased by 0.4% while that of RMB 134.2 million during the reporting period.
The group's profit for the period decreased by 40.6% from RMB 121.6 million for the six months ended June 30, 2022 to RMB 72.3 million during the reporting period. The group's net interest rate decreased from 18.4% in the six months ended June 30, 2022 to 9.8% in the reporting period.